The Best Venture Capital Investment category was open to biotech's and those investees from an international array of private equity, VCs and investment arms.
The criteria used to judge this category will be as follows:
â¢ Outline the structure of the deal, parties involved, what it covers and the responsibilities on both sides
â¢ Size of investees target market(s) and potential to progress strongly in the clinic / address unmet need
â¢ How the investment represents an innovative model. What aspect of the investment makes it unique
â¢ How the investing company has impacted the business (such as advancing clinical phases, creating of new jobs etc.)
â¢ Summary of the short / medium / long term potential of the investment
Winner: Vaxxas and One Ventures, Healthcare Ventures and Brandon Capital Partners
Judges specific comments on the winning investment included:
1. With a $16 million investment, this is one of Australia’s largest first round start-up investments that will allow company’s pursuit of commercially relevant research, including proof-of-concept demonstrations in humans and delivering vaccines with clinical studies
2. The significance of this investment is not just in its size. The investment syndicate, which includes both local and international investors, the Medical Research Commercialisation Fund (MRCF), the Brisbane Angels, and Boston-basedHealth Care Ventures provides a deep and diverse pool of expertise, knowledge and influence.
3. Its also worth noting in the wider industry vote, although not decisive, this company gained 41% of the 386 votes cast for this category
Well done Vaxxas and One Ventures, Healthcare Ventures and Brandon Capital Partners
Highly Regarded' recommendation: ImmusanT and Vatera Healthcare Partners for their $20m investment based on a single investor, rather than a syndicate.